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ABSTRACT
Background. Understanding the relationship between clinical and patient-reported outcomes (PROs) will help support
clinical care and future clinical trial design of novel therapies for focal segmental glomerulosclerosis (FSGS).
Methods. FSGS patients 8 years of age enrolled in the Nephrotic Syndrome Study Network completed Patient-Reported
Outcomes Measurement Information System PRO measures of health-related quality of life (HRQoL) (children: global
health, mobility, fatigue, pain interference, depression, anxiety, stress and peer relationships; adults: physical functioning,
fatigue, pain interference, sleep impairment, mental health, depression, anxiety and social satisfaction) at baseline and
during longitudinal follow-up for a maximum of 5 years. Linear mixed-effects models were used to determine which
demographic, clinical and laboratory features were associated with PROs for each of the eight children and eight adults
studied.
Results. There were 45 children and 114 adult FSGS patients enrolled that had at least one PRO assessment and 519
patient visits. Multivariable analyses among children found that edema was associated with global health (7.6 points,
P¼0.02) and mobility (4.2, P¼0.02), the number of reported symptoms was associated with worse depression (2.7 per
symptom, P¼0.009) and anxiety (2.3, P¼0.02) and the number of emergency room (ER) visits in the prior 6 months was
associated with worse mobility (2.8 per visit, P<0.001) and fatigue (2.4, P¼0.03). Multivariable analyses among adults
found the number of reported symptoms was associated with worse function in all eight PROMIS measures and the
number of ER visits was associated with worse fatigue, pain interference, sleep impairment, depression, anxiety and
social satisfaction. Laboratory markers of disease severity (i.e. proteinuria, estimated glomerular filtration rate and serum
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albumin) did not predict PRO in multivariable analyses, with the single exception of complete remission and better pain
interference scores among children (þ9.3, P ¼ 0.03).
Conclusions. PROs provide important information about HRQoL for persons with FSGS that is not captured solely by the
examination of laboratory-based markers of disease. However, it is critical that instruments capture the patient experience
and FSGS clinical trials may benefit from a disease-specific instrument more sensitive to within-patient changes.
Keywords: focal segmental glomerulosclerosis, nephrotic syndrome, patient-reported outcomes, PROMIS, prospective cohort
study, proteinuria, remission
BACKGROUND
Focal segmental glomerulosclerosis (FSGS) is a common cause
of nephrotic syndrome, frequently chronic and progressive in
nature, and accounts for 12% of children and 3% of adults with
incident end-stage kidney disease in the USA [1]. Currently the
most common initial therapy is high-dose glucocorticoids [2, 3].
Unfortunately, >70% of FSGS patients do not respond to gluco-
corticoid therapy and the prognosis is poor in these patients
[4, 5]. Alternative immunosuppressive therapies for FSGS may
improve disease control in 20–50% of the remaining patients,
but ultimately the disease course is chronic. Furthermore, im-
munosuppressive therapies are frequently associated with ad-
verse effects that compound disease-specific complications [6–
8]. As with the management of any chronic disease, in order to
provide the optimal care for each individual patient, it is critical
to understand and characterize the impact of disease on the
physical and psychosocial aspects of health-related quality of
life (HRQoL). In order to begin to achieve this goal, a critical first
step is to understand how HRQoL correlates with and diverges
from biochemical markers of disease activity.
Reduction and control of proteinuria are widely regarded to
be a major therapeutic goal in FSGS. Patients reaching either
complete or partial remission of proteinuria within the first 4–
8 months after kidney biopsy are significantly less likely to
progress to kidney failure [9]. Early work utilizing patient-
reported outcome (PRO) measures to evaluate HRQoL in chil-
dren with nephrotic syndrome has suggested that the disease
experience in nephrotic syndrome does not correlate entirely
with the traditional markers of disease activity [10–12]. One in-
terpretation of this finding is that the patient disease experi-
ence, such as physical limitations, missed school or work or
psychological aspects of chronic disease are not captured by
clinical laboratory values. A full understanding of this relation-
ship is critical, as PRO measures represent an invaluable tool to
optimize clinical care and enrich viable outcomes for clinical tri-
als [11]. In the context of clinical trial design, it is important to
understand the magnitude of change in HRQoL (as determined
by PROs) in response to changes in disease activity and whether
changes in HRQoL are distinct from changes in laboratory-
based markers. To date, no study has systematically evaluated
prospective clinical and laboratory features associated with
HRQoL in children and adults with FSGS, which represents a
critical step in the deployment of PROs into patient care and
clinical research [11].
The goal of this project was to assess HRQoL in children and
adults with FSGS and to identify key demographic, clinical and
laboratory predictors of these important outcomes in children
and adults. These associations are important because of the in-
creased attention that is being given to changes in HRQoL in
drug approval for rare diseases like FSGS with a large unmet
clinical need.
MATERIALS AND METHODS
Study design and participants
The Nephrotic Syndrome Study Network (NEPTUNE) is an ongo-
ing prospective observational cohort study of primary proteinu-
ric kidney diseases launched in 2010. Patients were enrolled at
the time of their first clinically indicated kidney biopsy [13]. For
patients enrolled prior to 2014, inclusion criteria included a
urine protein:creatinine ratio (UPCR) >0.5 g/g or 24-h urine total
protein >0.5 g/day; from 2014 onward, the inclusion criteria
were altered to a UPCR >1.5 g/g or 24-h urine total protein
>1.5 g/day. All NEPTUNE subjects with FSGS who completed
qualifying study visits by 23 May 2018 were included in these
analyses.
As part of this study, NEPTUNE subjects undergo detailed
clinical and laboratory phenotyping, including serial assess-
ments of HRQoL using PROs. Data capture includes demo-
graphic information, clinical information of symptoms,
diagnoses, physical examination, medications, laboratory val-
ues, collection of urine and blood biosamples, biopsy tissue,
PROs, hospitalizations, emergency department visits and proce-
dures. The study visit schedule includes a baseline assessment
within 30 days of the kidney biopsy and follow-up visits every
4 months for the first year and every 6 months thereafter for a
maximum of 5 years of follow-up [13]. Institutional review
board approval for this study was obtained at all participating
sites with appropriate consent and assent forms.
PROs
The Patient-Reported Outcomes Measurement Information
System (PROMIS) was developed through a National Institutes
of Health project that had the goal of improving the assessment
of HRQoL across diseases [14]. In the first round of measure
development, nine measures were developed. NEPTUNE used
the following PROMIS measures for children 8–17 years of age:
global health, fatigue, mobility, pain interference, anxiety,
depression, stress and peer relationships. NEPTUNE used the
following PROMIS measures for adults (18 years): physical
functioning, fatigue, pain interference, sleep impairment, men-
tal health, anxiety, depression and social relationships. While
NEPTUNE enrolls FSGS patients of all ages, these analyses
focused on patients with self-reported PROMIS assessments
and thus are limited to patients 8 years of age during study
participation.
PROMIS item banks were developed using an item response
theory approach used to determine each item’s discrimination
and the level of PRO severity each item is measuring. Each
PROMIS question used the context statement ‘In the past
7 days’. Responses included five options ranging from ‘never’ to
‘almost always’ in the majority of measures and from ‘with no
trouble’ to ‘not able to do’ for the mobility measure. PROMIS
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item bank scores range from 0 to 100. To aid interpretability
in these analyses, we transformed PROMIS scores so that higher
scores reflect better PROs for all measures.
Assessment of disease activity and severity
Proteinuria assessments in NEPTUNE are made from centrally
collected and assayed urine samples. UPCR values at 24 h were
used when available. If 24-h urine was not available, then spot
urine was used instead. In all analyses, proteinuria remission is
defined as complete remission (UPCR <0.3 g/g); partial remis-
sion (40% reduction in UPCR from baseline and UPCR between
0.3 and 1.5 g/g) and no response (did not meet either of the other
criteria) [9]. This modified definition of partial remission was
derived and validated in a recent study to define the optimal
proteinuria thresholds in predicting long-term outcomes, where
this novel definition performed slightly better than the conven-
tional partial remission definition of 50% reduction in UPCR
from baseline and baseline UPCR [15]. However, sensitivity anal-
yses will consider the conventional partial remission definition
as well.
Demographic characteristics examined as potential predic-
tors of HRQoL included age, sex, race, ethnicity and socioeco-
nomic status as assessed by education level. Education status
was dichotomized as less than a college education versus col-
lege education and above. For all adult participants over the age
of 24 years, the participant’s education level was used; the high-
est parental education level was used for all participants under
24 years of age.
Clinical characteristics included edema (qualitative assess-
ment by a clinician for any of the following: lower extremity, sa-
cral or anasarca), number of symptoms reported (symptom
questionnaire, including shortness of breath, swelling, fever,
chest pain, foamy urine, diarrhea, nausea/vomiting and a free
response for any additional symptoms), weight [categorized us-
ing body mass index (BMI) for adults and BMI percentile for chil-
dren], short stature (based on height) and health care utilization
in the past 6 months [collected number of emergency room
(ER) visits, wellness visits, illness/injury visits and hospitalizations].
Body weight was categorized as follows: underweight¼
BMI <18.5 kg/m2 in adults and BMI percentile <5th in children;
overweight ¼ BMI between 25 and 30 kg/m2 in adults and BMI per-
centile between 90th and 95th in children; obese ¼ BMI >30 kg/m2
in adults and BMI percentile >95th in children. Short stature in
children was defined as a height percentile <2.5% based on age
and sex; among adults, short stature was a height <152 cm in
females and <164 cm in males [16]. Medication burden was cap-
tured as the total number of medications the patient is currently
taking and as exposure to immunosuppressive medication.
Laboratory values included proteinuria (categorized as described
above), serum albumin and estimated glomerular filtration rate
(eGFR) calculated using the creatinine-based modified CKiD for-
mula in children and Chronic Kidney Disease Epidemiology
Collaboration equation in adults [17, 18].
Statistical analyses
Because there were different PRO instruments for children and
adult participants, all analyses were stratified by child versus
adult (8–17 versus 18 years). A linear mixed-effects model ap-
proach was used to evaluate the relationship between each
PROMIS score and each predictor of interest in a series of unad-
justed models. Random intercepts were fitted to account for the
repeated measures within individuals. All variables with an
unadjusted P-value <0.20 were tested in a backward multivari-
able model selection. Nonsignificant variables were removed in
reverse order of P-value until all remaining variables in the
model were significant at P < 0.05. All analyses were conducted
in SAS version 9.4 (SAS, Cary, NC, USA).
RESULTS
Data availability and description
A total of 176 NEPTUNE FSGS subjects were included in this
study (Figure 1). Five of these subjects were <8 years old and
thus were not eligible to complete the PROMIS self-report. Of
the remaining 171 subjects, 148 (87%) completed at least one
PROMIS instrument and 23 (13%) did not. The baseline charac-
teristics of the 148 with and 23 without PROMIS data were similar
by age, race, ethnicity, baseline eGFR and UPCR, disease duration
and immunosuppressive therapy exposure (Supplementary data,
Table S1). Subjects who completed the PROMIS assessment had
longer follow-up (median follow-up 43 versus 0 months;
P< 0.001), were less likely to be female (39% versus 65%; P¼ 0.002)
and were more likely to have edema (41% versus 22%; P< 0.001).
The baseline characteristics of the included 148 subjects are
shown in Table 1 separated by children and adults. Subjects
who reach the age of 18 years during follow-up may contribute
to both the child and adult analyses, as they completed the
child instrument until the age of 18 years and the adult instru-
ment afterward. There were a total 45 children and 114 adults
(112 child and 407 adult observations, respectively), which
includes 11 subjects contributing to both the child and adult
analyses. Children were more likely to be treated with immuno-
suppression at baseline (58% versus 23%; P< 0.001), more likely
to be female (53% versus 31%; P¼ 0.008) and had better-pre-
served kidney function at baseline (median eGFR 100 versus
58 mL/min/1.73 m2; P< 0.001). Participants completed a median
of 4 assessments [interquartile range (IQR) =2 to 4].
The distributions of all scores across all visits are shown in
Figure 2. The majority of measures had mean values close to 50
and standard deviations near 10. In general, 10–20% of observa-
tions were <40 (i.e. >1 SD less than the mean) and 10–20% were
>60 (domain-specific details in Supplementary data, Table S2).
PROMIS scores across all visits by proteinuria remission sta-
tus are shown in Table 2 for children and adults. Among child
visits, 25 were for children in complete remission, 16 in partial
remission and 71 in no remission. There were significant unad-
justed differences by remission status in pain interference (me-
dian complete remission 60.6 versus partial remission 43.8
versus no remission 48.2; P¼ 0.014) and anxiety (median com-
plete remission 61.8 versus partial remission 66.5 versus no re-
mission 58.0; P¼ 0.001), but subject-visit sample sizes were
small in the pediatric cohort. Adult analyses included 89 visits
for adults that were in complete remission, 57 in partial remis-
sion and 261 in no remission. In the adult unadjusted analyses,
complete remission was associated with better fatigue, mental
health, anxiety and social satisfaction. Partial remission was as-
sociated with higher mental health scores compared with no re-
mission (median 50.5 versus 45.7) but was associated with
similar fatigue (median 49.8 versus 49.3), anxiety (48.1 versus
48.8) and social satisfaction (51.6 versus 50.9) despite complete
remission being associated with higher scores for these
measures.
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Regression analyses
Unadjusted linear mixed effects models were completed for all
16 PROMIS PRO measures and all 19 predictors of interest. All
unadjusted results are shown in Supplementary data, Tables
S4–S19, and are summarized in Supplementary data, Figure S1.
Cells highlighted in red indicate variables that were statistically
significant unadjusted predictors of PRO scores (P< 0.05); cells
in orange are predictors that were not significant in unadjusted
models but were tested in multivariable model selection (P 
0.05–<0.20). The number of symptoms was a significant unad-
justed predictor of all adult measures and four of eight child
measures (and was included in model building for two
FIGURE 1: Flow diagram of included patients.
Table 1. Characteristics of NEPTUNE FSGS subjects who completed at least one PROMIS assessment
Characteristics
All subjects Children Adults
P-value(n¼ 148)a (n¼ 45) (n¼ 114)
Age (years), median (IQR) 33 (16–52) 13 (11–15) 43 (28–55) <0.001
Age at disease onset (years), median (IQR) 29 (14–47) 12 (6–14) 38 (26–52) <0.001
Female, n (%) 57 (38.5) 24 (53.3) 35 (30.7) 0.008
Race, n (%) 0.07
White or Caucasian 78 (52.7) 18 (40.0) 63 (55.3) –
Black or African American 48 (32.4) 21 (46.7) 35 (30.7) –
Other 17 (11.5) 3 (6.7) 14 (12.3) –
Unknown 5 (3.4) 3 (6.7) 2 (1.8) –
Hispanic ethnicity, n (%) 29 (19.6) 11 (24.4) 19 (16.7) 0.40
eGFR (mL/min/1.73 m2), median (IQR) 71 (48–100) 100 (71–115) 58 (42–91) <0.001
<30 14 (9.5) 0 (0%) 14 (12.3) –
30–59 48 (32.4) 5 (11.1) 45 (39.5) –
60–90 35 (23.6) 15 (33.3) 24 (21.1) –
>90 50 (33.8) 24 (53.3) 31 (27.2) –
Unknown 1 (0.7) 1 (2.2) 0 (0%) –
UPCR (g/g), median (IQR) 2.3 (1.0–4.7) 3.4 (1.2–7.7) 2.3 (1.0–3.6) 0.03
Edema, n (%) 60 (40.5) 20 (44.4) 44 (38.6) 0.50
Weight, n (%) 0.98
Underweight 3 (2.0) 1 (2.2) 2 (1.8) –
Normal weight 35 (23.6) 12 (26.7) 28 (24.6) –
Overweight 40 (27.0) 12 (26.7) 29 (25.4) –
Obese 70 (47.3) 20 (44.4) 55 (48.2) –
Follow-up (months), median (IQR) 43 (19–56) 44 (24–57) 44 (20–56) 0.50
Disease duration (months), median (IQR), months 4 (1–30) 2 (1–18) 4 (1–29) 0.44
On IST at baseline, n (%) 46 (31.1) 26 (57.8) 26 (22.8) <0.001
aDue to the longitudinal data collection with separate child and adult instruments, it is possible for patients to contribute to both the child and adult strata. There are
11 patients with both child and adult data.
IQR: interquartile range; IST: immunosuppressive therapy; underweight: BMI <18.5 in adults and BMI percentile <5th in children; overweight: BMI between 25 and 50
in adults and BMI percentile between 90th and 95th in children; obese: BMI >30 in adults and BMI percentile >95th in children.
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FIGURE 2: Distributions of PROMIS domain scores across all visits. Scores are transformed so that higher scores equal a better PRO.
Table 2. PROMIS domain scores by proteinuria remission status
Child PROMIS scores (n¼ 45 subjects, n¼112 observations)
PROMIS measure
Complete remission Partial remission No remission
P-value*(n¼ 25) (n¼ 16)a (n¼ 71)
Global health 48.6 (40.0–59.3) 32.5 (32.5–48.6) 40.0 (40.0–59.3) 0.25
Mobility 58.5 (48.5–58.5) 58.0 (44.6–58.5) 50.0 (43.5–58.5) 0.18
Fatigue 60.4 (49.9–64.9) 59.7 (50.2–69.7) 54.4 (44.0–66.5) 0.46
Pain interference 60.6 (51.5–67.8) 43.8 (41.7–46.2) 48.2 (44.7–54.1) 0.01
Depression 64.8 (55.9–64.8) 64.8 (57.3–64.8) 55.9 (46.5–64.8) 0.06
Anxiety 61.8 (55.8–66.5) 66.5 (65.8–67.6) 58.0 (46.0–66.5) 0.001
Stress 58.0 (49.2–58.0) 58.0 (43.3–58.0) 58.0 (43.3–58.0) 0.90
Peer relationships 48.7 (40.9–58.1) 51.6 (46.4–54.2) 50.3 (44.2–57.9) 0.99
Adult PROMIS scores (n¼ 114 subjects, n¼ 407 observations)







Physical functioning 49.8 (43.2–55.2) 49.8 (40.6–56.0) 47.4 (40.6–54.6) 0.13
Fatigue 53.4 (46.9–59.3) 49.8 (41.6–58.6) 49.3 (42.5–55.0) <0.001
Pain interference 48.0 (42.7–61.4) 49.9 (44.0–61.4) 49.9 (44.0–61.4) 0.99
Sleep-related impairment 49.8 (47.1–57.7) 48.7 (45.7–57.7) 47.1 (41.9–57.7) 0.07
Mental health 50.7 (43.9–56.8) 50.5 (43.6–60.0) 45.7 (42.0–53.1) 0.04
Depression 54.4 (48.7–56.7) 56.4 (49.0–58.3) 51.3 (45.0–57.4) 0.10
Anxiety 54.6 (46.5–63.7) 49.1 (42.0–63.7) 48.8 (41.5–55.7) <0.001
Social satisfaction 54.2 (50.0–67.8) 51.6 (44.7–67.8) 50.9 (43.4–58.8) 0.03
Scores are transformed so that higher scores equal a better PRO. Scores are presented as medians and interquartile ranges
aUPCR <1.5 g/g and 40% reduction in UPCR from baseline.
*Kruskall–Wallis test.
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additional measures). The number of ER visits entered model
selection for 13 measures. Other consistent predictors of PROs
included edema (which entered 11), number of medications (en-
tered 10), serum albumin (entered 10) and number of hospital-
izations (entered 9).
The results of final multivariable models are shown in
Tables 3 and 4 for children and adults, respectively. Some indi-
cators of more severe FSGS disease activity, namely edema,
symptom number and number of ER visits, were associated
with lower PRO scores. Among children (Table 3), edema was as-
sociated with worse global health (b ¼ 7.6, P¼ 0.02) and mobil-
ity (b ¼ 2.8, P¼ 0.0002). The number of symptoms was
associated with worse depression (b ¼ 2.7 per symptom,
P¼ 0.009) and anxiety (b ¼ 2.3 per symptom, P¼ 0.02) and the
number of ER visits in the past 6 months was associated with
worse mobility (b ¼ 2.8 per visit, P¼ 0.0002) and fatigue
(b ¼ 2.4 per visit, P¼ 0.03). Complete, but not partial, remission
was associated with better pain interference scores (b ¼ 9.3,
P¼ 0.03). Finally, an increased number of medications (b ¼ 1.1
per medication, P¼ 0.006) and older age (b ¼ 1.0 per year,
P¼ 0.04) was associated with worse fatigue and renin–angioten-
sin–aldosterone system blockade therapy with worse stress
(b ¼ 4.4, P¼ 0.04).
As shown in Table 4, the number of symptoms was retained
as a significant predictor in each of the eight adult final models,
with effect size estimates ranging from 0.9 to 1.5 per symp-
tom. The number of ER visits was associated with worse fatigue,
pain interference, sleep impairment, depression, anxiety and
social satisfaction (effect size estimates per symptom ranging
from 1.3 to 1.6). Higher education level was consistently as-
sociated with better scores for physical functioning, fatigue,
pain interference, mental health and social satisfaction (effect
size estimates ranging from 3.1 to 5.0). The number of medica-
tions was associated with worse anxiety (b¼0.3 per medica-
tion, P¼ 0.009) and social satisfaction (b¼0.3 per medication,
P¼ 0.02); weight status, particularly being severely obese, was
associated with worse physical functioning (b¼4.9, P¼ 0.001)
and depression scores (b ¼3.2, P¼ 0.004) and diuretics with
worse mental health (b¼3.3, P¼ 0.03).
Complete remission was associated with better pain inter-
ference scores among children but was not retained in any of
the final adult models. Sensitivity analyses tested for differen-
ces when using the conventional partial remission definition of
50% reduction in UPCR from baseline and UPCR between 0.3
and 3.5 g/g. PROMIS scores by visit are shown in Supplementary
data, Table S3. Unadjusted differences for child, anxiety, adult,
fatigue, mental health, anxiety and social satisfaction were
retained. Conventional and novel remission status were 94%
concordant. In this sensitivity analysis, remission status was
the sole predictor of child pain interference after multivariable
adjustment: complete remission was associated with a 10.0 im-
provement in score versus no remission (95% confidence inter-
val 1.59–18.3); there was no difference between partial and no
remission, as was found using the modified proteinuria remis-
sion definition.
DISCUSSION
This study examined the longitudinal relationship between a
number of demographic and clinical characteristics of disease
activity and HRQoL in 148 patients with FSGS. In general, the
strongest and most consistent predictors of HRQoL were symp-
tom burden (measured by the total number of symptoms or
presence of edema) and health care utilization (measured by
the number of ER visits). Although proteinuria reduction is used
as the primary endpoint in most clinical trials of FSGS, protein-
uria remission was only significantly associated with pain
in children and was not associated with any aspect of self-
reported HRQoL in adults. These findings suggest that
laboratory-based values, such as proteinuria and eGFR, are not
strongly associated with the day-to-day patient disease experi-
ence. As such, the inclusion of PROs that evaluate HRQoL offers
an opportunity to understand unique aspects of the disease ex-
perience that may help optimize clinical care and clinical trials
for patients with FSGS.
These findings are consistent with the previous assessment
examining the association between changes in self-reported
HRQoL and changes in disease status among a cohort of chil-
dren with nephrotic syndrome (though not necessarily FSGS)
[19]. In a cross-sectional analysis of 151 children with nephrotic
syndrome (66 specifically with FSGS), children with active
edema had significantly worse mobility, fatigue, pain interfer-
ence and anxiety when compared with children with no edema
[20]. A higher degree of pain interference was also observed
among patients with a longer duration of active disease [21]. In
a longitudinal analysis of PROMIS in 127 children with nephrotic
syndrome (16 specifically with FSGS), remission of proteinuria
was not associated with changes in PROMIS mobility, fatigue,
pain interference, depression or anxiety [11]. Previous cross-
sectional analyses among children have shown cross-sectional
relationships with both proteinuria and PROMIS measures and
edema and PROMIS measures, with a stronger relationship
found for edema [12, 22]. Edema and the number of symptoms
were also the strongest cross-sectional predictors of HRQoL in a
Table 3. Final adjusted mixed effects model for clinical and labora-
tory predictors of HRQoL domains among children
Characteristics b (95% CI) P-value
Global health
Edema 7.6 (13.8 to 1.5) 0.02
Mobility
Edema 4.2 (7.7 to 0.8) 0.02
Number of ER visits in past 6 months 2.8 (4.2 to 1.4) 0.0002
Fatigue
Age (per year) 1.0 (1.9 to 0.1) 0.04
Number of ER visits in past 6 months 2.4 (4.6 to 0.3) 0.03
Number of medications 1.1 (1.8 to 0.3) 0.006
Pain interference
Proteinuria – 0.02
Partial remission 6.0 (14.1–2.1) 0.13
Complete remission 9.3 (1.2–17.4) 0.03
No remission Ref Ref
Depression
Number of symptoms 2.7 (4.7 to 0.7) 0.009
Anxiety
Number of symptoms 2.3 (4.2 to 0.3) 0.02
Stress
On RAAS blockade 4.4 (8.6 to 0.2) 0.04
Peer relationships
No predictors – –
Scores are transformed so that higher scores equal a better PRO.
b: linear regression coefficient (i.e. difference in group means); CI: confidence in-
terval; REF: reference; underweight: BMI <18.5 in adults and BMI percentile <5th
in children; overweight: BMI between 25 and 50 in adults and BMI percentile be-
tween 90th and 95th in children; obese: BMI >30 in adults and BMI percentile
>95th in children.
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large sample of children and adults with glomerular disease
[22, 23].
One possible interpretation of these results is that changes
in HRQoL simply are not as closely related to changes in labora-
tory markers such as proteinuria and that perhaps even an
FSGS-specific PRO instrument would only correlate modestly
with remission status or edema. It may be that improvements
in laboratory markers, such as UPCR and eGFR, by themselves
are not associated with drastic improvements in HRQoL if they
are not accompanied by improvements in symptom manage-
ment or adverse side effects of medications. Instead, changes in
HRQoL are more accurately predicted by changes in symptom
burden and health care utilization. If this interpretation is true,
then this would still stress the importance of measuring PRO as
a distinct outcome in clinical trials of novel therapies rather
than assuming that improvements in proteinuria or eGFR are
associated with better HRQoL. Clinical trials that focus on pro-
teinuria reduction as the primary endpoint may not reflect
what affects patients’ HRQoL. As such, trials focusing on im-
proving HRQoL as the primary outcome (or perhaps as a co-
primary outcome) rather than proteinuria remission alone may
be justified.
An alternative interpretation is that the PROMIS HRQoL
measures do not adequately track FSGS- or nephrotic
syndrome–related aspects of HRQoL. Developing a disease-spe-
cific instrument may be necessary to better detect within-
patient changes associated with changes in proteinuria and
immunosuppressive therapy use. PROMIS was developed to
measure HRQoL concepts that were broadly applicable to per-
sons with chronic health conditions. But the absence of a rela-
tionship with immunosuppressive therapy may suggest that
these PROMIS measures do not ask the most relevant questions
of patients with FSGS. Thus, while these instruments are able to
distinguish between patients with a worse phenotype [12, 22],
these instruments do not appear sensitive enough to detect
more subtle within-patient changes in disease status, at least
among patients with nephrotic syndrome [11]. However, as
others have postulated, it could be possible that the null rela-
tionship with immunosuppressive therapy use could be due to
counterbalancing negative and positive impacts on HRQoL,
namely, negative impact from the well-known side effect pro-
files, positive impact from disease control and positive
impact from optimism associated with a perceived treatment
benefit [22].
While the PROMIS instrument may lack sufficient precision
to serve as an outcome for a Phase 2 FSGS clinical trial, certain
domains or uses may be more helpful as a clinical tool to track
within-patient changes. Physical domains, such as fatigue, tend
to have higher correlations with disease activity than mental
health or social domains and may be more relevant to patients.
The extreme ends of the PROMIS distributions might also be
more informative. Distributions of scores in this study found
subsets of patients with particularly high or low values. Clinical
applications might simply indicate if a score is high or low if it
is >1 standard deviation from the mean, instead of over-
interpreting small continuous differences, and would identify
patients with the strongest HRQoL impairments. Additionally,
approaches that combine scores from multiple domains may be
helpful. For example, among children and adults with nephrotic
syndrome, latent profile analysis, a mixture modeling approach
used to create categorical latent variables from observed contin-
uous variables, has been used to stratify patients into distinct
categories of good versus average versus poor HRQoL [24]. The
same approach has been used in children with cancer [25]. This
Table 4. Final adjusted mixed effects model for clinical and labora-
tory predictors of HRQoL domains among adults
b (95% CI) P-value
Physical functioning
College education 3.2 (0.4–6.0) 0.03
Number of symptoms 1.0 (1.5 to 0.5) 0.0002
Weight 0.001
Underweight 6.3 (11.4 to 1.2)
Overweight 2.8 (5.3 to 0.2)
Obese 4.9 (7.7 to 2.1)
Severe obesity 6.4 (10.1 to 2.7)
Normal weight Ref Ref
Number of illness/injury vis-
its in past 6 months
0.1 (0.2 to 0.1) 0.01
Fatigue
Female versus male 4.6 (7.8 to 1.3) 0.006
College education 3.1 (0.1–6.2) 0.04
Number of symptoms 1.2 (1.8 to 0.6) <0.0001
Number of ER visits in past
6 months
1.3 (2.2 to 0.5) 0.002
Pain interference
Age (per year) 0.2 (0.3 to 0.1) 0.01
College education 4.3 (0.2–8.3) 0.04
Number of symptoms 1.2 (2.1 to 0.4) 0.005
Number of ER visits in past
6 months
1.6 (2.8 to 0.3) 0.01
Sleep impairments
Number of symptoms 0.9 (1.6 to 0.3) 0.005
Number of ER visits in past
6 months
1.5 (2.5 to 0.6) 0.001
Mental health
College education 4.0 (0.3–7.7) 0.04
Number of symptoms 1.5 (2.7 to 0.4) 0.01
On diuretics 3.3 (6.2 to 0.4) 0.03
Depression





Severe obesity 11.6 (17.4 to 5.8)
Normal weight Ref Ref
Number of ER visits in past
6 months
1.4 (2.7 to 0.1) 0.04
Anxiety
Number of symptoms 1.4 (2.1 to 0.6) 0.0003
Number of ER visits in past
6 months
1.3 (2.3 to 0.2) 0.02
Number of medications 0.3 (0.5 to 0.1) 0.009
Social satisfaction
College education 5.0 (1.0–8.9) 0.01
Edema 2.7 (5.1 to 0.3) 0.02
Number of symptoms 1.4 (2.3 to 0.6) 0.001
Number of ER visits in past
6 months
2.2 (3.5 to 0.9) 0.0008
Number of medications 0.3 (0.6 to 0.1) 0.02
Scores are transformed so that higher scores equal a better PRO.
b: linear regression coefficient (i.e. difference in group means); CI: confidence in-
terval; Ref: reference; underweight: BMI <18.5 in adults and BMI percentile <5th
in children; overweight: BMI between 25 and 50 in adults and BMI percentile be-
tween 90th and 95th in children; obese: BMI >30 in adults and BMI percentile
>95th in children.
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type of latent variable approach would likely be not suitable for
a clinical trial, but could be helpful in comprehensive patient
management.
This study is not without limitations. The pediatric meas-
ures are limited to those 8–17 years of age and, at the time of
data collection, only an English-language assessment was avail-
able and validated. Additionally, NEPTUNE FSGS enrollees en-
tered at the time of the first kidney biopsy, and results might
not generalize to patients with a long history of prevalent dis-
ease. Another limitation is the lack of a quantified assessment
of edema severity [22]. Additionally, many patients presented
with subnephrotic-range proteinuria, but findings may be dif-
ferent in a sample with more extreme proteinuria. Despite these
limitations, this study adds value to the growing literature of
PRO in patients with nephrotic syndrome and is the first longi-
tudinal study of PRO in pediatric and adult FSGS patients.
Importantly, this study found that HRQoL is most strongly
predicted by symptoms and health care utilization and not by
laboratory-based markers of disease activity. At the very least,
changes in proteinuria do not necessarily correspond to
changes in HRQoL. Many patients see an improvement in pro-
teinuria without an analogous improvement in HRQoL and vice
versa. This study emphasizes the importance of studying clini-
cal outcomes separately from patient-reported HRQoL. While
proteinuria may serve as an early marker of progression to kid-
ney disease [9], its relationship with PROMIS-based estimates of
HRQoL is weak. Given the known side-effect burden of current
immunosuppressive therapies used to treat FSGS, we recom-
mend that disease-specific PROs be developed to incorporate
patient-identified concepts. In addition, we recommend that
clinical trials of novel therapies incorporate PROs as trial end-
points alongside proteinuria and kidney survival–based
endpoints.
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